Upper Endoscopy in Ulcerative Colitis Patients in Assiut University

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06092593
Collaborator
(none)
70
21

Study Details

Study Description

Brief Summary

Aim of study:
Primary Outcomes:

Patients with ulcerative colitis-associated upper gas- trointestinal inflammation may require specific treat- ment for the gastroduodenal lesions. Hence, recogni- tion and detection of the upper gastrointestinal lesions are important. Here we describe 2 cases of ulcerative colitis and summarize the results of our investigation of the prevalence of upper gastrointestinal involvement detected by esophagogastroduodenoscopy. We also analyzed the macroscopic and microscopic features of the upper gastrointestinal lesions

Secondary Outcomes:

correct and timely treatment of upprt GIT lesions in UC .

Condition or Disease Intervention/Treatment Phase
  • Device: Upper endoscopy

Detailed Description

Ulcerative colitis (UC) is an idiopathic, chronic, relapsing inflammatory bowel disease (IBD) occurring in the colon and rectum . The main typical symptoms of UC include frequent bowel movement, mucus pus, bloody diarrhea, abdominal pain and discomfort, urgency, weight loss, and tenesmus . Apart from these typical symptoms, emerging evidence supports that there are a variety of accompanying symptoms involving the upper gastrointestinal (UGI) tract in patients with UC upon macroscopic and microscopic analyses, such as eosinophilic esophagitis[9], gastroduodenitis, ulcers, or UGI inflammation In addition, the positive rate of UGI endoscopy in asymptomatic individuals was lower than that in symptomatic patients. The reported clinically significant UGI lesions include multiple erosions, granular changes, white spots, friable mucosa, ulcer, and purulent deposits during fibrogastroduodenoscopy (FGDS)[ط UGI involvement may be unnoticed by the attending physician due to the lack of the knowledge of gastroduodenal lesions, which should raise concerns during UC treatment. Furthermore, there is no established standard or criteria available for patients with UC who should undergo FGDS , because the clinical backgrounds of these patients with UC-associated UGI lesions have not been fully and exactly demonstrated. Specific management may be required for patients with UC-associated UGI lesions. Henceforth, we conducted this study with the aim of describing various UGI tract presentations in UC and their differential diagnosis

Study Design

Study Type:
Observational
Anticipated Enrollment :
70 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Evaluation of Upper Gastrointestinal Tract Lesions in Ulcerative Colitis Patients in Assiut University
Anticipated Study Start Date :
Jan 1, 2024
Anticipated Primary Completion Date :
Jan 1, 2025
Anticipated Study Completion Date :
Oct 1, 2025

Outcome Measures

Primary Outcome Measures

  1. Evaluation of upper gastrointestinal tract lesions in ulcerative colitis patients [Baseline]

    The relationship between ulcerative colitis patients and upper gastrointestinal tract lesions

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Patients' age is 18 years or above.

  • Patient who are diagnosed with UC..

  • Patient who are fit to undergo upper endoscopy .

Exclusion Criteria:
  • Pediatric patients.

  • patient refuse to participate at this study

  • patient with known upper GIT disorder .

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Gamal Abdelnasser Gaber Ahmed, Principal investigator, Assiut University
ClinicalTrials.gov Identifier:
NCT06092593
Other Study ID Numbers:
  • Upper endoscopy UC
First Posted:
Oct 23, 2023
Last Update Posted:
Oct 23, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 23, 2023